Modifiable Cardiovascular Risk and the Efficacy of Icosapent Ethyl: A REDUCE-IT Secondary Analysis - 07/08/25
Doi : 10.1016/j.hlc.2025.06.537
G. Figtree 1, R. Aggarwal 2, D. Bhatt 3, M. Miller 4, C. Ballantyne 5, E. Brinton 6, T. Jacobson 7, S. Ketchum 8, J. Tardif 9, M. Budoff 10, P. Steg 11
1 The University of Sydney, Sydney, NSW, Australia
2 Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA
3 Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA
4 Department of Medicine, Crescenz Veterans Affairs Medical Center and University of Pennsylvania School of Medicine, Philadelphia, PA, USA
5 Department of Medicine, Baylor College of Medicine, and the Texas Heart Institute, Houston, TX, USA
6 Utah Lipid Center, Salt Lake City, UT, USA
7 Lipid Clinic and Cardiovascular Risk Reduction Program, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
8 Amarin Pharma, Inc., Bridgewater, NJ, USA
9 Montreal Heart Institute, Université de Montréal, Montreal, Québec, Canada
10 Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, USA
11 Université Paris-Cité, Assistance Publique-Hôpitaux de Paris and INSERM U1148, Paris, France
521
Le texte complet de cet article est disponible en PDF.Plan
© 2025
Publié par Elsevier Masson SAS.
Vol 34 - N° S4
P. S429-S430 - août 2025 Retour au numéro
Article précédent
- Mineralocorticoid Receptor Antagonist Prescription Patterns Post-STEMI: A Single-Centre Quality Improvement Audit From An Australian Tertiary Hospital
- P. Brown, J. Shute, R. Lambert, P. Dhonde, R. Jayasinghe
- My Ears Were Rocking
- K. Peiris, L. Chean, S. Sidharta, R. Garg
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?